RUNX2 and Hepatic fibrosis: Expectedly, CWHM‐12, a novel small molecule inhibitor therapeutically targeting all αv integrins effectively, was shown to significantly reduce liver fibrosis,20, 45 which was also observed in our study, and more importantly, CWHM‐12 could prevent the liver fibrosis aggravation caused by Runx2 overexpression.